French network of hepatic tumor biobanks
Friday, April 19, 2019
    

Latest events

05/19-20/2016: Certification audit
04/25/2016: Strategic committee (visioconference)
03/29/2016: Training of Clinical Research technicians
01/26/2016: Management review (Paris)
10/22-23/2015: Certification audit
10/13/2015: Strategic committee (visioconference)
09/30/2015: AFEF Researchers Meeting (Toulouse)
06/16/2015: Strategic committee (Paris)
04/14/2015: Strategic committee (Paris)
01/13/2015: Management review (Paris)
09/24/2014: AFEF researchers meeting : Partners invitation
04/19/2012: Congress EASL Barcelone : Presentation of the network (report)
04/17/2012: Meeting with INCA (program)

Main data of the database

Inclusions

Samples

Needle biopsy

Parafin enbedded
Number according to etiology:
Entre 0 et 10%
Deep frozen
Number according to etiology:
Entre 0 et 10%

Samples (deep frozen)

Number according to etiology:
Entre 90 et 100%

Etiologies

HBV

HBV DNA positive:
Entre 0 et 10%

HCV

HCV RNA (PCR) positive:
Entre 10 et 20%

HIV

Coinfection HIV/HBV:
Entre 0 et 10%
Coinfection HIV/HCV:
Entre 0 et 10%

Alcohol

Single etiology:
Entre 10 et 20%
Several etiologies:
Entre 10 et 20%

Hemochromatosis

Single etiology:
Entre 0 et 10%
Several etiologies:
Entre 0 et 10%

NASH

Single etiology:
Entre 0 et 10%
Several etiologies:
Entre 0 et 10%

Tumours and fluids

Hepato cellulase carcinomateux

Blood sample:
Entre 0 et 10%
Serum sample:
Entre 10 et 20%
Plasma sample:
Entre 0 et 10%
Stools sample:
Entre 0 et 10%
Paxgene samples:
Entre 0 et 10%

Cholangiocarcînoma

Blood sample:
Entre 10 et 20%
Serum sample:
Entre 30 et 40%
Plasma sample:
Entre 0 et 10%
Stools sample:
Entre 0 et 10%
Paxgene samples:
Entre 0 et 10%

Benign tumour

Blood sample:
Entre 0 et 10%
Serum sample:
Entre 0 et 10%
Plasma sample:
Entre 0 et 10%
Stools sample:
Entre 0 et 10%
Paxgene samples:
Entre 0 et 10%

Differentation stage

Degree of differenciation of HCC:
NamesNumber of tumours
PeuEntre 0 et 10%
BienEntre 40 et 50%
MoyennementEntre 40 et 50%
Degree of differenciation of CCk:
NamesNumber of tumours
PeuEntre 10 et 20%
BienEntre 30 et 40%
MoyennementEntre 50 et 60%

Fibroseis stage of non tumorous liver

Number of patients with cirrhosis F4:
Entre 30 et 40%
Number of patients with fibrosis F3-F2:
Entre 10 et 20%
Number of patients with normal liver F0-F1:
Entre 10 et 20%

Newsletters

Liver cancer biobanks network in France : Inventory in 2014 DRCD Newsletter of June, 2012 August 2011 October 2010
Applicants
How submit a research project ?
Project submission form
Database search
Restricted access
Access to the restricted site
Help
For all questions or technical difficulties, please send an email to: credim.support.dev